MCMaressa C. Criscito

Maressa C. Criscito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maressa C. Criscito has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • John A. Carucci

    The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

    7 shared publications
  • Mary L. Stevenson

    The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

    6 shared publications
  • John A. Carucci

    The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

    5 shared publications
  • Michelle C. Juarez

    The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

    4 shared publications
  • Nayoung Lee

    The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

    3 shared publications
  • Reason Wilken

    Department of Dermatology, Northwell Health, New York, USA

    3 shared publications

Latest Publications

  • Laser and Light‐Based Therapies in Inflammatory Dermatoses: A Systematic Review of Safety, Efficacy, and Adverse Effects to Inform Cosmetic Use

    by Carli Tucci, Richard Li, Farida Ettefa, Maressa C. Criscito, Lisa O. Akintilo

    Objectives: Laser and light‐based therapies are widely used in dermatology, yet patients with inflammatory dermatoses are often excluded from cosmetic procedures due to concerns for disease exacerbation. This systematic review evaluated the safety and efficacy of these modalities to inform their use. Methods: A PRISMA‐guided search of PubMed, Embase, ClinicalTrials.gov, and Scopus from inception through March 1, 2026 identified studies of adults with psoriasis, atopic dermatitis, lichen sclerosus, lichen planus pigmentosus, frontal fibrosing alopecia, or cutaneous sarcoidosis treated with laser or light‐based therapies. Eligible studies reported clinical outcomes and adverse events; reviews and studies without attributable outcomes were excluded. Risk of bias was assessed qualitatively, and results were synthesized descriptively. Results: Fifty‐seven studies including over 900 patients were analyzed, with the strongest evidence in psoriasis and lichen sclerosus. Across conditions and device types, therapies consistently demonstrated clinical improvement and were generally well tolerated. Adverse effects were predominantly localized and transient, including erythema, edema, blistering, and pigmentary changes. Serious adverse events were rare, with only isolated cases of koebnerization or disease worsening reported. Limitations include heterogeneity and predominance of small or non‐randomized studies. Conclusions: These findings suggest that, in appropriately selected patients, laser and light‐based therapies are safe and do not consistently precipitate disease exacerbation.

  • Positive Surgical Margins Affect Nodal Metastasis and All-Cause Mortality in Merkel Cell Carcinoma: A National Cancer Database Study 2004 to 2022

    by Carli Tucci, Akshay Pulavarty, Michelle C. Juarez, Nayoung Lee, Mary L. Stevenson, Maressa C. Criscito, John A. Carucci

    BACKGROUND: Merkel cell carcinoma (MCC) is a highly aggressive cutaneous malignancy. Guidelines recommend surgical excision with histologically negative margins for clinically node-negative disease. Adjuvant radiation therapy (aRT) is recommended for positive margins; however, its ability to offset the adverse impact of residual microscopic disease remains uncertain. OBJECTIVE: Evaluate the association between surgical margin status and oncologic outcomes among patients treated with excision and aRT. METHODS: Using the National Cancer Database (2004–2022), the authors identified patients with cN0 MCC who underwent excision followed by aRT with documented margin status. Multivariable logistic regression assessed predictors of regional lymph node metastasis, and Cox modeling evaluated all-cause mortality. RESULTS: Among 7,510 patients, 11.7% had positive surgical margins. Margin positivity was more common in older patients, head and neck tumors, and higher T-stage disease. Positive margins were independently associated with increased odds of regional lymph node metastasis (aOR 1.57, 95% confidence interval CI 1.24–1.99; p < .001) and higher all-cause mortality (HR 1.60, 95% CI 1.43–1.78; p < .001). CONCLUSION: Their findings suggest that positive surgical margins are an adverse prognostic factor despite aRT. Achieving histologically negative margins remains an important prognostic consideration in the management of MCC.

  • Lichen Sclerosus Is Associated With an Increased Risk of Anal Cancer: A TriNetX Retrospective Cohort Study

    by Sophie Jabban, Robert Adler, Akshay Pulavarty, Maressa C. Criscito, Miriam Keltz Pomeranz

  • Platelet‐Rich Plasma Injections and Scalp Cutaneous Malignancies: Clinical Implications and Knowledge Gaps

    by Archie Spindler, Derek Maas, Isabella Zappi, Olivia Perez, Lynn Petukhova, Nicole Doudican, John Carucci, Jennifer A. Stein, Jerry Shapiro, Maressa C. Criscito, et al.

    Platelet‐rich plasma (PRP) injections are an effective and increasingly utilized treatment for androgenetic alopecia; however, the delivery of concentrated growth factors raises theoretical concerns regarding cutaneous malignancy risk in chronically ultraviolet (UV)‐exposed, hair‐thinning scalps. In this article, the current hypotheses linking PRP to scalp skin cancer risk are reviewed, including potential oncogenic mechanisms, such as platelet‐derived growth factor (PDGF)‐mediated signaling, and protective effects, such as improved hair‐mediated photoprotection and antiproliferative findings from related blood products, although direct PRP‐specific data remain lacking. Overall, the available evidence supports PRP safety while underscoring the need for prospective studies, routine scalp surveillance, and patient counseling regarding photoprotection.

  • Clinical characteristics and outcome of base-involving cutaneous squamous cell carcinoma in situ

    by Derek Maas, Zasca-Aisha Ristianto, Carli Tucci, Akshay Pulavarty, Nayoung Lee, Mary L. Stevenson, John A. Carucci, Maressa C. Criscito

  • Characterizing basal cell carcinoma incidence in the United States using a nationally representative dataset

    by Akshay N. Pulavarty, Lauren Stone, Michelle C. Juarez, John A. Carucci, Maressa C. Criscito

  • Open Access

    Self supervised artificial intelligence predicts poor outcome from primary cutaneous squamous cell carcinoma at diagnosis

    by Nicolas Coudray, Michelle C. Juarez, Maressa C. Criscito, Adalberto Claudio Quiros, Reason Wilken, Stephanie R. Jackson Cullison, Mary L. Stevenson, Nicole A. Doudican, Ke Yuan, Jamie D. Aquino, et al.

    Primary cutaneous squamous cell carcinoma (cSCC) is responsible for ~10,000 deaths annually in the United States. Stratification of risk of poor outcome at initial biopsy would significantly impact clinical decision-making during the initial post operative period where intervention has been shown to be most effective. Using whole-slide images (WSI) from 163 patients from 3 institutions, we developed a self supervised deep-learning model to predict poor outcomes in cSCC patients from histopathological features at initial diagnosis, and validated it using WSI from 563 patients, collected from two other academic institutions. For disease-free survival prediction, the model attained a concordance index of 0.73 in the development cohort and 0.84 in the Mayo cohort. The model’s interpretability revealed that features like poor differentiation and deep invasion were strongly associated with poor prognosis. Furthermore, the model is effective in stratifying risk among BWH T2a and AJCC T2, known for outcome heterogeneity.


  • Racial and ethnic differences in healthcare access and utilization among U.S. adults with melanoma and keratinocyte carcinomas in the NIH All of Us Research Program

    by Michelle C. Juarez, Jill T. Shah, Nayoung Lee, Mary L. Stevenson, John A. Carucci, Maressa C. Criscito

    There is a paucity of information on racial and ethnic disparities relating to barriers to care in healthcare access and utilization in patients with cutaneous malignancies. We conducted a cross-sectional analysis of adults with melanoma, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) in the National Institutes of Health (NIH) All of Us Research Program collected between May 2018 and July 2022. Participants included adults (aged 18 or older) with cutaneous malignancy who completed the Health Care Access and Utilization survey. We identified 5,817 adults who were diagnosed with BCC (67%), cSCC (28.9%), and melanoma (23.9%). Non-Hispanic Black (NHB) and Hispanic patients were more likely than non-Hispanic White (NHW) patients to delay a primary care visit due to cost (p = 0.005 and p = 0.015, respectively). NHB patients were also more likely to delay care due to lack of transportation (p < 0.001). NHB and Hispanic patients were more likely to place importance on seeing a provider from the same background (NHB p < 0.002; Hispanic p = 0.002) and also were more likely to report never being able to see such a provider (NHB p < 0.001; Hispanic p = 0.002). Medicaid/Medicare patients, non-college graduates, and those with lower incomes also faced increased barriers to care, including delays due to cost and transportation issues. People of color with cutaneous malignancies are more likely to delay care in seeing primary care providers due to cost or transportation issues. This study provides important insights on disproportionate healthcare usage among racial/ethnic groups that may help mitigate healthcare disparities.


  • Artificial Intelligence in Dermatology: A Systematic Review of Its Applications in Melanoma and Keratinocyte Carcinoma Diagnosis

    by Neil Jairath, Vartan Md Pahalyants, Rohan Bs Shah, Jason Weed, John A. Carucci, Maressa C. Criscito

    BACKGROUND: Limited access to dermatologic care may pose an obstacle to the early detection and intervention of cutaneous malignancies. The role of artificial intelligence (AI) in skin cancer diagnosis may alleviate potential care gaps. OBJECTIVE: The aim of this systematic review was to offer an in-depth exploration of published AI algorithms trained on dermoscopic and macroscopic clinical images for the diagnosis of melanoma, basal cell carcinoma, and cutaneous squamous cell carcinoma (cSCC). METHODS: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, a systematic review was conducted on peer-reviewed articles published between January 1, 2000, and January 26, 2023. RESULTS AND DISCUSSION: Among the 232 studies in this review, the overall accuracy, sensitivity, and specificity of AI for tumor detection averaged 90%, 87%, and 91%, respectively. Model performance improved with time. Despite seemingly impressive performance, the paucity of external validation and limited representation of cSCC and skin of color in the data sets limits the generalizability of the current models. In addition, dermatologists coauthored only 12.9% of all studies included in the review. Moving forward, it is imperative to prioritize robustness in data reporting, inclusivity in data collection, and interdisciplinary collaboration to ensure the development of equitable and effective AI tools.